Australian AI health‑tech firm Everlab secured $46 million in a new financing round led by Sydney‑based Airtree Ventures, with participation from New York’s Left Lane Capital. The capital infusion aims to fund the company’s push beyond the domestic market, targeting Europe and North America where demand for predictive care solutions is rising, and attract strategic partnerships with insurers and providers.

Everlab’s platform aggregates clinical notes, imaging reports and pathology results, then layers them with real‑time metrics from users’ wearables. By normalising disparate data streams, the system claims it can flag emerging conditions before they require costly interventions. Investors see the approach as a way to reduce hospital admissions and tap into preventive‑care reimbursement models for insurers and employers alike.

The deal lifts Everlab’s valuation into the mid‑hundreds of millions, positioning it alongside other AI‑driven diagnostics firms courting global health systems. With the funding secured, the startup plans to scale its engineering team and launch pilot programs in major hospitals. Success will hinge on regulatory clearance and the ability to integrate with existing electronic health record platforms for better outcomes.